Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Director John Gordon Freund Sells 6,601 Shares

Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) Director John Gordon Freund sold 6,601 shares of the firm's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $30.62, for a total value of $202,122.62. Following the transaction, the director now owns 70,658 shares in the company, valued at approximately $2,163,547.96. This represents a 8.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Collegium Pharmaceutical Stock Down 1.4%

NASDAQ COLL traded down $0.42 during trading on Friday, hitting $29.18. The company's stock had a trading volume of 227,489 shares, compared to its average volume of 414,163. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a market cap of $937.61 million, a PE ratio of 12.58 and a beta of 0.63. The business's 50 day simple moving average is $28.18 and its 200-day simple moving average is $29.57. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). The business had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Collegium Pharmaceutical's revenue was up 22.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.45 EPS. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 248.5% during the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company's stock worth $19,338,000 after purchasing an additional 461,914 shares during the period. Invesco Ltd. lifted its holdings in shares of Collegium Pharmaceutical by 19.5% during the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company's stock worth $50,876,000 after purchasing an additional 289,335 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Collegium Pharmaceutical by 319.4% during the fourth quarter. Janus Henderson Group PLC now owns 291,388 shares of the specialty pharmaceutical company's stock worth $8,341,000 after purchasing an additional 221,903 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth about $3,489,000. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Collegium Pharmaceutical by 18.1% during the first quarter. Massachusetts Financial Services Co. MA now owns 713,854 shares of the specialty pharmaceutical company's stock worth $21,309,000 after purchasing an additional 109,655 shares during the period.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Needham & Company LLC reiterated a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $37.00 target price (up previously from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $43.75.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.